SCHEMBL21376629

SCHEMBL21376629

O=C(NCc1ccccc1Cl)NC[C@H](NC(=O)c1c(Cl)cncc1Cl)C(=O)O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.55
RAB9A P51151 1/20 0.55
ITGA4 P13612 4/20 0.51
ITGB1 P05556 3/20 0.50
CASR P41180 1/20 0.49
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49
KCNA5 P22460 1/20 0.46
ITGB7 P26010 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
ANPEP P15144 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2C19 P33261 1/20 0.46
ALDH1A1 P00352 2/20 0.44
SCN2A Q99250 1/20 0.44
SCN10A Q9Y5Y9 1/20 0.44
ITGAV P06756 1/20 0.44
ITGA5 P08648 1/20 0.44
HDAC3 O15379 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21376398 0.91 NPC1 (0.60) NPC1RAB9AITGA4ITGB1CASR
SCHEMBL24106001 0.91 NPC1 (0.60) NPC1RAB9AITGA4ITGB1CASR
SCHEMBL21358699 0.88 ITGA4 (0.55) ITGA4ITGB1ITGB7ALDH1A1ITGAV
SCHEMBL21358701 0.88 ITGA4 (0.55) ITGA4ITGB1ITGB7ALDH1A1ITGAV
SCHEMBL21376369 0.83 ITGA4 (0.54) ITGA4ITGB1ITGB7ALDH1A1
SCHEMBL21376376 0.82 ITGA4 (0.51) NPC1RAB9AITGA4ITGB1MEN1
SCHEMBL21376627 0.82 ITGA4 (0.56) ITGA4ITGB1MEN1KMT2AITGB7
SCHEMBL21358742 0.82 ITGB1 (0.53) NPC1RAB9AITGA4ITGB1ITGB7
SCHEMBL21358743 0.82 ITGB1 (0.53) NPC1RAB9AITGA4ITGB1ITGB7
SCHEMBL24106054 0.81 ALDH1A1 (0.50) NPC1RAB9AITGA4ITGB1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11597727-B2 Inhibitors of integrin alpha 2 beta 1 and methods of use THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-03-07 US disclosed
US-20210387986-A1 INHIBITORS OF INTEGRIN ALPHA 2 BETA 1 AND METHODS OF USE THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2021-12-16 US disclosed
WO-2019178248-A1 INHIBITORS OF INTEGRIN ALPHA 2 BETA 1 AND METHODS OF USE THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2019-09-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11597727-B2 Inhibitors of integrin alpha 2 beta 1 and methods of use ITGB1, ITGB2, ITGA2 NPC1 2243/4885RAB9A 1527/4885ITGA4 15/4885
US-20210387986-A1 INHIBITORS OF INTEGRIN ALPHA 2 BETA 1 AND METHODS OF USE ITGB1, ITGB2, ITGA2 NPC1 2243/4885RAB9A 1527/4885ITGA4 15/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.